Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Nautilus Biotechnology Inc

Company price
2.12 USD -0.05 ( 2.30%)
Last update at 2026-11-20T21:00:00Z
VOLUME
6223767
Market Cap
113.24M

Momentum Score

…

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.91
Low
2.17
High
52 Week Price Range
0.68
Low
4.31
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.17
Dividend Yield
-
Revenue TTM
0.19M
Revenue Per Share
0.00
Gross Profit TTM
0.17M
Debt / Equity
0.19
ROE
-36.21%
Net Debt
17.63M
ROCE
-32.21%
Diluted EPS TTM
-0.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -59.00M -70.78M -63.67M -57.92M -50.31M
Net income -59.00M -70.78M -63.67M -63.74M -50.31M
Selling general administrative 25.73M 31.00M 28.90M 25.95M 21.15M
Selling and marketing expenses - - 3.86M - -
Gross profit -6.46M -6.35M -5.71M - -
Reconciled depreciation 6.46M 6.35M 5.04M 3.42M 2.84M
Ebit -59.00M -70.78M -63.67M -63.62M -50.50M
Ebitda -52.54M -64.43M -61.83M -60.20M -47.66M
Depreciation and amortization 6.46M 6.35M 1.85M 3.42M 2.84M
Non operating income net other - - - -0.12M 0.18M
Operating income -66.84M -81.48M -76.15M -63.62M -50.50M
Other operating expenses 66.84M 81.48M 76.15M 63.62M 50.50M
Interest expense - - - 5.82M 0.18M
Interest income 7.87M 10.78M 12.40M 5.82M -
Net interest income 7.87M 10.78M 12.40M 5.82M -
Income tax expense - -70.78M - 5.82M -0.18M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 60.37M 75.12M 70.45M 63.62M 50.50M
Cost of revenue 6.46M 6.35M 5.71M - -
Total other income expense net 7.84M 10.70M 12.48M 5.69M 0.18M
Net income from continuing ops -59.00M -70.78M -60.06M -57.92M -50.31M
Net income applicable to common shares - - - -57.92M -50.31M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 191.11M 242.74M 305.56M 350.05M 398.45M
Other current assets 2.56M 2.93M 3.42M 2.74M 3.49M
Total liab 34.14M 34.01M 40.21M 35.13M 34.87M
Total stockholder equity 156.97M 208.73M 265.35M 314.92M 363.58M
Other current liab 3.18M 2.55M 0.38M 3.53M 0.39M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -332.02M -273.02M -202.24M -138.56M -80.64M
Other assets - - - 1.11M 1.00M
Cash 12.39M 27.65M 19.40M 114.52M 185.62M
Total current liabilities 7.95M 7.63M 9.12M 6.79M 5.81M
Current deferred revenue - - 3.57M - 2.73M
Net debt 17.63M 2.83M 15.23M -84.19M -155.59M
Short term debt 3.83M 4.10M 3.54M 1.99M 0.97M
Short long term debt total 30.02M 30.48M 34.63M 30.33M 30.03M
Other stockholder equity 488.74M 481.68M 467.83M 455.33M 45.94M
Property plant equipment - - - 3.70M 2.48M
Total current assets 105.96M 132.83M 176.84M 187.21M 349.22M
Long term investments 52.74M 76.41M 90.65M 129.17M 16.37M
Net tangible assets - - - 314.92M 363.58M
Short term investments 91.02M 102.25M 154.02M 69.95M 160.11M
Accounts payable 0.94M 0.99M 1.64M 1.27M 1.72M
Accumulated other comprehensive income 0.24M 0.06M -0.26M -1.85M -0.18M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -138.56M -80.64M
Non currrent assets other 1.18M 1.18M 1.18M 1.11M 1.00M
Non current assets total 85.15M 109.92M 128.73M 162.84M 49.23M
Capital lease obligations 30.02M 30.48M 34.63M 30.33M 30.03M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 36.50M 66.25M -66.73M -25.74M -136.69M
Change to liabilities - - - -0.15M 3.52M
Total cashflows from investing activities 35.22M 66.25M -43.73M -25.74M -138.96M
Total cash from financing activities 0.21M 1.14M 0.37M 0.56M 327.45M
Change to operating activities - - - -0.23M -1.28M
Net income -59.00M -70.78M -63.67M -57.92M -50.31M
Change in cash -15.26M 8.25M -95.08M -70.98M 149.24M
Begin period cash flow 28.65M 20.40M 115.48M 186.46M 37.22M
End period cash flow 13.39M 28.65M 20.40M 115.48M 186.46M
Total cash from operating activities -50.70M -59.15M -51.71M -45.81M -39.24M
Issuance of capital stock - - - - 0.00M
Depreciation 6.46M 6.35M 5.71M 3.42M 2.84M
Other cashflows from investing activities 108.99M -0.76M - - -
Sale purchase of stock 0.16M 0.52M 0.26M 0.23M -7.96M
Other cashflows from financing activities 0.21M 1.14M 0.37M -25.74M 327.45M
Change to netincome - - - 10.38M 8.07M
Capital expenditures 1.28M 2.12M 2.44M 2.32M 2.27M
Cash flows other operating - - - 1.56M -1.72M
Cash and cash equivalents changes - - - -70.98M 149.24M
Change in working capital -3.58M -5.46M -3.22M -0.79M -0.02M
Stock based compensation 6.84M 12.70M 12.14M 10.38M 7.93M
Other non cash items -1.42M -1.96M -2.66M -0.89M 0.32M
Free cash flow -51.97M -61.27M -54.15M -48.13M -41.51M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NAUT
Nautilus Biotechnology Inc
-0.05
2.30%
2.12 - - 596.83 0.88 5911.00 -2.00
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Nautilus Biotechnology Inc

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

2701 Eastlake Avenue East, Seattle, WA, United States, 98102

206 333 2001

127

Name Title Year Born
Mr. Sujal M. Patel Co-Founder, CEO, Pres, Sec. & Director 1975
Dr. Parag Mallick Ph.D. Co-Founder, Chief Scientist & Director 1977
Mr. Matthew B. Murphy ESQ. Gen. Counsel 1965
Ms. Anna Mowry CFO & Treasurer NA
Ms. Mary E. Godwin Sr. VP of Operations 1959
Mr. Chris Blessington VP of Corp. Marketing & Communications NA
Ms. Gwen E. Weld Chief People Officer 1958
Mr. Nick A. Nelson Chief Bus. Officer & Sr. VP of Bus. Devel. 1983
Dr. Subra Sankar Ph.D. Sr. VP of Product Devel. 1959
Mr. Sujal M. Patel Co-Founder, CEO, President, Secretary & Director 1975

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…